Cover Image
市場調查報告書

過敏性鼻炎:日本的醫藥品市場預測與市場分析

Allergic Rhinitis - Japan Drug Forecast and Market Analysis to 2024

出版商 GlobalData 商品編碼 371768
出版日期 內容資訊 英文 174 Pages
訂單完成後即時交付
價格
Back to Top
過敏性鼻炎:日本的醫藥品市場預測與市場分析 Allergic Rhinitis - Japan Drug Forecast and Market Analysis to 2024
出版日期: 2015年09月01日 內容資訊: 英文 174 Pages
簡介

本報告提供日本的過敏性鼻炎治療藥市場相關調查分析,提供您疾病概要和治療指南,競爭情形,主要藥物的詳細資訊 (產品說明,安全性,有效性) 、SWOT分析,銷售額預測,影響分析 (趨勢,推動因素·阻礙因素) 等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
  • 症狀
  • 分類
  • 診斷
  • QOL

第4章 疾病的管理

  • 診斷和治療概要
  • 日本

第5章 競爭評估

  • 概要
  • 口服H1抗組織胺藥物
  • 經鼻抗組織胺藥物
  • 經鼻皮質類固醇
  • 經鼻皮質類固醇/抗組織胺藥物的配合
  • 充血消除藥
  • 經鼻抗膽鹼藥
  • 白三烯素受體拮抗劑
  • Cromones
  • 凝血脂素A2受體拮抗劑
  • TH2細胞激素抑制劑

第6章 未滿足需求和機會

  • 概要
  • 藥劑師的教育
  • 使用經鼻皮質類固醇·抗組織胺藥物時的服藥遵守
  • 便利性高,減輕患者負擔的免疫療法
  • 基層醫療醫生教育

第7章 開發平台評估

  • 臨床開發中的有前途藥物
    • S-555739
    • HP-3060

第8章 市場預測

  • 日本
    • 預測
    • 主要的活動
    • 推動因素·障礙

第9章 附錄

圖表

目錄
Product Code: GDHC318CFR

AR is becoming an increasingly prevalent condition, with the most common form being moderate to severe in nature (Baena-Cagnani et al., 2015). According to the European Academy of Allergy and Clinical Immunology (EAACI), 50% of Europeans will suffer from an allergy by 2027 (Papadopoulos et al., 2012). The allergic rhinitis (AR) market has declined very slowly over the past decade, as has it become saturated with relatively efficacious standard therapies, such as antihistamines (AHs), intranasal corticosteroids (INCS), and leukotriene receptor antagonists (LRAs), and has also been facing increasing generic competition. Despite the rising prevalence of AR, and a large patient population that is dissatisfied with the current treatment options, the market size for symptomatic therapies alone is set to shrink, as the remaining branded products lose patent protection. There is an increasing shift in the transfer of prescription AR products to over-the-counter (OTC) status, which is driving patients to pharmacies rather than to physicians, further diluting the prescription AR market. The immense, crowded generic AR market has been largely unappealing to drug manufacturers. Consequently, only two symptomatic therapies are expected to launch before 2024.

Sales of AR products in Japan were $1.89 billion in 2014. As in the global markets, the growth in the Japanese AR market will be fueled mainly by the uptake of the new AITs, and will be offset by the patent expiry of the best-selling AHs in 2013, and Merck's INCS, Nasonex, in 2017.

Scope

  • Overview of Allergic Rhinitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in Japan from 2014-2024.
  • Analysis of the impact of key events as well the drivers and restraints affecting Japan Allergic Rhinitis market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Allergic Rhinitis.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2014-2024 in Japan.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
  • 3.2. Symptoms
  • 3.3. Classification
    • 3.3.1. Seasonal and Perennial AR
    • 3.3.2. ARIA Classification of AR
  • 3.4. Diagnosis
  • 3.5. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice
  • 4.2. Japan

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Oral H1 Antihistamines
    • 5.2.1. Overview
    • 5.2.2. Efficacy
    • 5.2.3. Safety
    • 5.2.4. SWOT Analysis
    • 5.2.5. Forecast
  • 5.3. Intranasal Antihistamines
  • 5.4. Intranasal Corticosteroids
    • 5.4.1. Overview
    • 5.4.2. Efficacy
    • 5.4.3. Safety
    • 5.4.4. SWOT Analysis
    • 5.4.5. Forecast
  • 5.5. Combination Intranasal Corticosteroids/Antihistamines
    • 5.5.1. Dymista
  • 5.6. Decongestants
    • 5.6.1. Overview
  • 5.7. Intranasal Anticholinergics
    • 5.7.1. Overview
  • 5.8. Leukotriene Receptor Antagonists
    • 5.8.1. Overview
  • 5.9. Cromones
    • 5.9.1. Overview
  • 5.10. Thromboxane A2 Receptor Antagonists
    • 5.10.1. Overview
  • 5.11. TH2. Cytokine Inhibitors
    • 5.11.1. Overview

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Pharmacist Education
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Patient Compliance With Intranasal Corticosteroids and Antihistamines
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. More Convenient and More Patient-Friendly Immunotherapies
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Primary Care Physician Education
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity

7. Pipeline Assessment

  • 7.1. Promising Drugs in Clinical Development
    • 7.1.1. S-555739
    • 7.1.2. HP-3060

8. Market Outlook

  • 8.1. Japan
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Pediatric Allergic Rhinitis Population
    • 9.4.2. Diagnosed AR Patients
    • 9.4.3. Percentage of Drug-Treated Patients
    • 9.4.4. Drugs Included in Each Therapeutic Class
    • 9.4.5. Launch and Patent Expiry Dates
    • 9.4.6. 1General Pricing Assumptions
    • 9.4.7. Individual Drug Assumptions
    • 9.4.8. Generic Erosion
    • 9.4.9. Pricing of Pipeline Agents
  • 9.5. Physicians and Specialists Included in This Study
  • 9.6. About the Authors
    • 9.6.1. Analyst
    • 9.6.2. Therapy Area Director
    • 9.6.3. Epidemiologist
    • 9.6.4. Global Head of Healthcare
  • 9.7. About GlobalData
  • 9.8. Disclaimer

List of Tables

  • Table 1: Airborne Allergens That Cause AR
  • Table 2: Common Symptoms of AR
  • Table 3: Treatment Guidelines for AR
  • Table 4: Most Commonly Prescribed Drugs for AR in the 7MM by Class, 2014
  • Table 5: Major Brands of INCS
  • Table 6: Management of AR, Country Profile - Japan
  • Table 7: Effects of Main Drug Classes on AR Symptoms
  • Table 8: Leading Branded Drugs Used to Treat AR, 2014
  • Table 9: Major Brands of Second- and Third-Generation Non-Sedating AHs
  • Table 10: Product Profile - AHs
  • Table 11: Efficacy of Bilastine in Symptomatic SAR Patients Age 12-70 Years
  • Table 12: Safety of Bilastine in Symptomatic SAR Patients Age 12-70 Years
  • Table 13: Oral AHs SWOT Analysis, 2014
  • Table 14: Global Sales Forecasts ($m) for Oral AHs, 2014-2024
  • Table 15: Major Brands of Intranasal Ahs
  • Table 16: Major Brands of INCS
  • Table 17: Product Profile - INCS
  • Table 18: Efficacy of FP ANS and BDP ANS in AR Patients Age 18-72 Years
  • Table 19: Safety Profile of FP ANS and BDP ANS in AR Patients Age 18-72 Years
  • Table 20: INCS SWOT Analysis, 2014
  • Table 21: Global Sales Forecasts ($m) for INCS, 2014-2024
  • Table 22: Product Profile - Dymista
  • Table 23: Efficacy of Dymista
  • Table 24: Safety of Dymista
  • Table 25: Dymista SWOT Analysis, 2014
  • Table 26: Global Sales Forecasts ($m) for Dymista, 2014-2024
  • Table 27: Unmet Need and Opportunity in AR
  • Table 28: Late-Stage Pipeline for AR, 2014
  • Table 29: Product Profile - S-555739
  • Table 30: Completed Clinical Trials of S-555739 in AR Patients
  • Table 31: S-555739 SWOT Analysis, 2014
  • Table 32: Global Sales Forecasts ($) for S-555739, 2014-2024
  • Table 33: Product Profile - HP-3060
  • Table 34: HP-3060 SWOT Analysis, 2014
  • Table 35: Global Sales Forecasts ($) for HP-3060, 2014-2024
  • Table 36: Sales Forecasts ($) for AR in Japan, 2014-2024
  • Table 37: Key Events Impacting Sales for AR in Japan, 2014-2024
  • Table 38: AR Market - Drivers and Barriers in Japan, 2014-2024
  • Table 39: Abbreviations
  • Table 40: Key Launch Dates of the Currently Available AR Therapies
  • Table 41: Key Loss of Exclusivity Dates of the Currently Available AR Therapies
  • Table 42: High-Prescribing Physicians (non-KOLs) Surveyed, by Country

List of Figures

  • Figure 1: Immunological Mechanisms Involved in the Early- and Late-Phase Allergic Response
  • Figure 2: ARIA Classification of AR by Duration of Symptoms and Severity
  • Figure 3: Algorithm Used for the Management of AR in the 7MM*
  • Figure 4: Sales for AR in Japan by Drug Class, 2014-2024
Back to Top